Peptide Chemistry
How Research Peptides Are Made: From Resin to Lyophilized Powder
Last updated:
Short Answer
Synthetic research peptides are most often made by solid-phase peptide synthesis: the first amino acid is anchored to an insoluble resin and the chain is built one residue at a time, in a repeating cycle of deprotection, washing, coupling and washing [1]. The finished chain is cleaved from the resin, purified by reversed-phase HPLC and freeze-dried to a powder [2]. No step goes perfectly to completion, so the powder holds related impurities as well as the target peptide, and its mass also includes counter-ions and water [2, 3].
The short version
Synthetic research peptides are most often made by solid-phase peptide synthesis (SPPS) [1], which proceeds in seven stages. This guide describes general published chemistry, not any specific supplier's lots.
- 1. Anchoring. The C-terminal amino acid is attached to an insoluble resin [1].
- 2. Cycling. The N-terminal protecting group of the growing chain is removed, the resin is washed, the next protected, activated amino acid is coupled, and the resin is washed again; the cycle repeats for each residue [1].
- 3. Cleavage. In Fmoc chemistry, trifluoroacetic acid (TFA) containing scavengers releases the chain from the resin and removes side-chain protecting groups [4, 5].
- 4. Precipitation. The crude peptide is isolated by antisolvent precipitation; in one published protocol the solvent was ice-cold diethyl ether [5].
- 5. Purification. Preparative reversed-phase HPLC separates the target from related impurities [2].
- 6. Freeze-drying. Pooled fractions are lyophilized to a fine white powder [2, 3].
- 7. Analysis. Identity, purity and content are measured on the finished powder [3].
Where synthesis starts: the resin and the first residue
The central idea of solid-phase synthesis is to anchor the first amino acid to an insoluble polymer, so excess reagents and by-products are removed by filtration and washing after every step instead of isolating each intermediate. The finished chain is released only at the end [6]. Merrifield introduced the approach in a 1963 paper on the synthesis of a tetrapeptide on a solid support [6, 7], and he received the 1984 Nobel Prize in Chemistry, alone, for developing a methodology for chemical synthesis on a solid matrix [8].
The first residue anchored is the C-terminal one, so chains grow toward the N-terminus [1, 9]. Each building block carries a temporary protecting group on the alpha-amine, removed every cycle, and permanent groups on reactive side chains, kept until the end [9].
Two schemes recur in the literature. Merrifield's Boc/benzyl scheme used acid-labile Boc for temporary protection and benzyl-based side-chain groups, with the finished peptide released by anhydrous HF [5, 6]. A 1978 report described Fmoc amino acids removed by mild base (piperidine), avoiding repeated acid deprotection and HF cleavage [10]. In Fmoc/tBu chemistry the Fmoc group is removed by base, while tBu-based side-chain groups and common resin linkages are removed by TFA, an orthogonal scheme [9, 11]. A 2016 review states that most synthetic peptides are now made by Fmoc SPPS, with Boc generally used for specialist applications [11].
The synthesis cycle: deprotect, couple, wash, repeat
Each residue is added by the same four operations [1]. Deprotect: the temporary N-terminal protecting group is removed. Wash: the reagent is rinsed away. Couple: the next protected, activated amino acid is attached. Wash: excess reagents and soluble by-products are rinsed away. Because the chain stays on the insoluble resin, washing is a simple filtration [1].
Why a cycle is never 100% complete. Each step is a reaction on a solid support and can stop short of completion. Deletion sequences, which lack one or more residues, arise when a coupling does not finish [6, 12]. Merrifield noted that a quantitative ninhydrin test can detect about 0.1% unreacted chains, that is, 99.9% coupling [6].
Small losses compound. The 1984 Nobel announcement illustrated the arithmetic for a peptide of about 100 residues: it called a 90% yield per step a very good yield for conventional synthesis with isolation of each intermediate, which would give about 0.003% overall after 100 steps, and said that solid-phase synthesis had made 99.5% per step or better attainable, which would give about 61% overall [8]. A 2007 protocol paper describes aggregation of the growing chain on the resin as the main cause of failure in chemical peptide synthesis [13].
Cleavage and deprotection
In standard Fmoc/tBu synthesis TFA is not used in the repeated deprotection cycles; it is used at the final step, where TFA containing scavengers cleaves the peptide from the resin and removes side-chain protecting groups in one operation [4, 5, 11]. Scavengers are included because protecting groups and linkers liberated by TFA can otherwise modify Trp, Tyr, Met and Cys [4], and because tert-butyl cations can migrate to other positions in the peptide [5].
In Boc/benzyl chemistry the equivalent step uses anhydrous HF, a very strong acid that generates carbocations able to alkylate Tyr, Trp, Met and Cys, so scavengers such as anisole are included [6]. HF is described as undesirable, and Fmoc SPPS uses the less hazardous TFA for the final cleavage [5]. After cleavage the crude peptide is typically isolated by antisolvent precipitation; in one published protocol the TFA solution was added to ice-cold diethyl ether [5].
What is collected is a mixture: the target peptide with deletion, truncated, incompletely deprotected and modified peptides, residual reagents and protecting-group by-products [2].
Purification by reversed-phase HPLC
Standard purification is preparative reversed-phase HPLC on C18-modified silica (C8 is also used) with UV detection at 210-220 nm [2, 14]. Polar contaminants elute first in aqueous 0.1% TFA, and the acetonitrile proportion (also with 0.1% TFA) is raised gradually, so peptides elute by increasing hydrophobicity [2, 14].
TFA and acetonitrile are widely used because they are volatile, which suits preparative purification and avoids a separate desalting step, and because the low pH prevents ionic interactions between basic residues and free silanol groups; TFA also acts as an ion-pairing agent [14, 15].
Fractions are checked by analytical HPLC, and sufficiently pure fractions are pooled and freeze-dried, or purified further [2, 14]. If standard RP-HPLC methods do not give sufficient purity, alternative RP-HPLC conditions, such as different solvents or buffers, may be used [2]. Orthogonal modes such as mixed-mode HILIC/cation-exchange or capillary electrophoresis can complement RP-HPLC [14].
Lyophilization
Lyophilization is freeze-drying: the pooled, purified fractions are frozen and the solvent is removed, leaving a fine white powder; water cannot be removed completely [2, 3]. TFA is not completely removed either: part is bound as a salt to basic sites, and part can remain adsorbed in the lyophilizate [2, 3, 15].
Peptides are often hygroscopic, and adsorption of water may decrease stability and reduce the overall peptide content [16]. Laboratory handling is covered in How to Store Lyophilized Peptides.
What can go wrong: common impurity types
Merrifield's 1984 lecture grouped the principal by-products as termination, deletion and modification peptides [6]. Termination peptides are chains whose growth stopped; they are also called truncated peptides.
| Impurity type | How it arises | How testing sees it |
|---|---|---|
| Deletion peptide | A coupling step did not reach completion [6, 12]. | A frequent type of HPLC-detectable impurity [12]. |
| Truncated (capped) peptide | Chain growth stops. Acetic acid contamination of some Fmoc building blocks causes permanent capping [11]. | Appears as a separate impurity peak, lowering HPLC purity, if it resolves from the main peak, and is hidden inside the main peak if it co-elutes (a consequence of how peak-area purity is defined [3]). The acetic acid contaminant itself is not detected by RP-HPLC [11]. |
| Incompletely deprotected peptide | Side-chain protecting groups remain after cleavage. A review notes that peptides with several Arg residues still need extended cleavage times for complete Pbf removal [11]. | A study using extracted-ion LC-MS tracked residual Pbf (+252 Da) and tert-butyl (+56 Da) adducts as mass shifts [5]. |
| Modified residues | Protecting groups and linkers liberated during TFA cleavage can modify Trp, Tyr, Met or Cys [4], and tert-butyl groups can end up at other positions in the peptide [5]. Met can oxidize to Met-sulfoxide and Trp to oxidation products [5]. | Mass shifts: Met-sulfoxide and the primary Trp oxidation products (5-hydroxytryptophan, oxindolylalanine) are +16 Da; tert-butyl adducts are +56 Da [5]. |
| Epimers (racemization) | Cys and His can racemize during coupling, particularly with base-mediated activation; for Cys, racemization is described as particularly high with pre-activation and microwave heating [11]. | Depends on the method; the aspartimide row shows an example that is hard to resolve by RP-HPLC [11]. |
| Aspartimide-related by-products | In Fmoc chemistry, Asp-containing sequences can cyclize to an aspartimide on exposure to base (piperidine), to a degree that depends strongly on the following residue (Asp-Gly is the worst case), which makes it a particular problem for long peptides and sequences with several Asp residues. It can give rise to nine different by-products, including D/L alpha- and beta-aspartyl peptides and piperidides, and is described as the most serious unwanted reaction of Fmoc chemistry [11]. | Some co-elute with the target on RP-HPLC. The epimerized alpha-aspartyl peptide is described as very difficult or impossible to resolve; piperidides are usually easy to separate [11]. |
One synthetic peptide can carry many related impurities: an analytical reference-material study identified more than 65 structurally related impurities in a single synthetic peptide material, about 8% of the material by mass [17]. A 2019 study of a 39-residue peptide reported that several by-products often share a retention time, making simple UV peak-area integration unreliable for specific impurities, so extracted-ion LC-MS was used to quantify them [5].
TFA counter-ion, water and net peptide content
A lyophilized peptide is not 100% peptide. When a peptide is made by Fmoc/tBu SPPS with TFA cleavage and RP-HPLC in TFA, cationic peptides are commonly obtained as trifluoroacetate salts, with TFA bound to the free N-terminus and to basic side chains (Arg, Lys, His) [2, 3, 15]. Water is also present [3].
HPLC purity is the main-peak area as a percentage of total peak area, typically from UV detection at 210-220 nm; it does not measure counter-ions, water or residual solvents [3, 12]. Net peptide content (NPC) is the fraction of peptidic material (target plus peptidic impurities) relative to counter-ions and residual water; gross weight is the total mass of peptide, counter-ions and adhered water [3, 18]. An NPC of 85% means 85 parts of peptidic material in every 100 parts of gross weight [18]. NPC can be estimated from nitrogen content, since counter-ions and water contain no nitrogen, or by amino acid analysis [3, 18]. Metrology work on peptide reference materials likewise lists amino acid analysis, nitrogen determination and mass balance among approaches for assigning peptide purity [17].
The two numbers answer different questions. One manufacturer's published handling guidance states that the peptide content of a lyophilized solid may range from 70 to 90% because of counter-ions and residual moisture [16]; that is one manufacturer's statement, not an industry standard. A low NPC is expected for peptides rich in basic residues (Arg, Lys, His), because of salt formation, and for hydrophilic peptides that absorb considerable moisture, even when very pure by HPLC [3].
Why this matters when reading a certificate of analysis
A certificate reports measurements made on the finished powder, so it helps to know what each type of number reflects; which of them a given certificate includes varies. Published quality-control guidance separates three questions [3]. Identity is checked by mass spectrometry (molecular weight), co-elution with a reference sample, and amino acid analysis, which gives composition but no sequence information [3]. Purity is the HPLC peak-area percentage under the stated method [3, 12]. Content is separate: water by Karl Fischer titration, residual solvents by gas chromatography, acetic acid by HPLC or ion chromatography, residual TFA by ion chromatography, and nitrogen by elemental analysis [3].
Read against that background, a high HPLC purity does not state how much of the powder is peptide, because counter-ions, water and residual solvents are outside the measurement [3, 12]. Identity and purity are also different questions, set out in the HPLC vs LC-MS guide. And a by-product that co-elutes with the target is counted inside the main peak, which is why some aspartimide-derived species are hard to see by HPLC purity alone [11]. For the certificate itself, see how to read a COA.
Research use only
Laboratory research use only. Not for diagnostic or therapeutic use. See the research use policy.
References
- 1.Bachem. Solid Phase Peptide Synthesis (SPPS) explained. Bachem Knowledge Center. 2023 (page dated 5 June 2023; accessed October 2026). Source
- 2.Bachem. Peptide Purification Process & Methods: An Overview (Guide chapter 5/10). Bachem Knowledge Center. Accessed October 2026. Source
- 3.Bachem. Quality Control of Amino Acids & Peptides: A Guide (Guide chapter 7/10). Bachem Knowledge Center. Accessed October 2026. Source
- 4.King DS, Fields CG, Fields GB. A cleavage method which minimizes side reactions following Fmoc solid phase peptide synthesis. Int J Pept Protein Res. 1990;36(3):255-266. PubMed 2279849
- 5.Pawlas J, Svensson T, Rasmussen JH. 1,4-Benzenedimethanethiol (1,4-BDMT) as a scavenger for greener peptide resin cleavages. RSC Adv. 2019;9(67):38928-38934. PubMed 35540669
- 6.Merrifield RB. Solid Phase Synthesis (Nobel Lecture, 8 December 1984). In: Nobel Lectures, Chemistry 1981-1990. Singapore: World Scientific; 1992. Source
- 7.Merrifield RB. Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide. J Am Chem Soc. 1963;85(14):2149-2154. doi:10.1021/ja00897a025
- 8.Royal Swedish Academy of Sciences. Press release: The 1984 Nobel Prize in Chemistry. NobelPrize.org. 17 October 1984. Source
- 9.Bachem. Peptide Manufacturing: Step-By-Step Guide (Guide chapter 4/10). Bachem Knowledge Center. Accessed October 2026. Source
- 10.Chang CD, Meienhofer J. Solid-phase peptide synthesis using mild base cleavage of N-alpha-fluorenylmethyloxycarbonylamino acids. Int J Pept Protein Res. 1978;11(3):246-249. PubMed 649259
- 11.Behrendt R, White P, Offer J. Advances in Fmoc solid-phase peptide synthesis. J Pept Sci. 2016;22(1):4-27. PubMed 26785684
- 12.Bachem. Peptide Content & Concentration Calculator (explanatory text). Bachem Knowledge Center. 2021 (page dated 22 January 2021; accessed October 2026). Source
- 13.Coin I, Beyermann M, Bienert M. Solid-phase peptide synthesis: from standard procedures to the synthesis of difficult sequences. Nat Protoc. 2007;2(12):3247-3256. PubMed 18079725
- 14.Mant CT, Chen Y, Yan Z, Popa TV, Kovacs JM, Mills JB, Tripet BP, Hodges RS. HPLC analysis and purification of peptides. Methods Mol Biol. 2007;386:3-55. PubMed 18604941
- 15.Sikora K, Jaskiewicz M, Neubauer D, Migon D, Kamysz W. The Role of Counter-Ions in Peptides - An Overview. Pharmaceuticals (Basel). 2020;13(12):442. PubMed 33287352
- 16.Bachem. Care and Handling of Peptides. Bachem Knowledge Center. 2021 (page dated 23 January 2021; accessed October 2026). Source
- 17.Li M, Josephs RD, Daireaux A, Choteau T, Westwood S, Wielgosz RI, Li H. Identification and accurate quantification of structurally related peptide impurities in synthetic human C-peptide by liquid chromatography-high resolution mass spectrometry. Anal Bioanal Chem. 2018;410(20):5059-5070. PubMed 29862433
- 18.Bachem. Frequently Asked Questions (Knowledge Hub FAQ: assay, gross weight, net peptide content). Bachem Knowledge Center. Accessed October 2026. Source